^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Ovarian Cancer
    Drug:avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Phase I Trial of VS-6766 Alone and in Combination With Everolimus

    Excerpt:
    ...Documented presence of RAS-RAF-MEK pathway mutations including BRAF, KRAS and NRAS....
    Trial ID:
    DDU RAF/MEK
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.

    Published date:
    05/30/2017
    Excerpt:
    Of the gynaecological cancers, 3/5 patients (60%) achieved a partial response (KRAS-mutant endometrial and ovarian cancer and BRAF-mutant ovarian). RO5126766 has shown exciting preliminary activity across a wide range of RAS- and RAF-mutated malignancies, with significant response rates in lung and gynaecological cancers.
    DOI:
    10.1200/JCO.2017.35.15_suppl.2506
    Trial ID:
    DDU RAF/MEK